AC Immune (ACIU) EBITDA Margin (2015 - 2025)
AC Immune's EBITDA Margin came in at -4161.24% for the quarter ended Dec 31, 2025, down 2555.35 percentage points from -1605.89% a year earlier and down 2475.83 percentage points from the prior quarter.
Powered by 
Analysis
AC Immune (ACIU) EBITDA Margin (2015 - 2025) Analysis & Trends
For the year ended Dec 31, 2025, AC Immune's EBITDA Margin was -1901.06%, down 1714.70 percentage points from the prior year.
- EBITDA Margin carries a five-year change of -1514.02 percentage points (years ended Dec 2020 to Dec 2025).
- Going back by year, EBITDA Margin was -186.36% in the year ended Dec 31, 2024 (+164.64 pp), -351.00% in the year ended Dec 31, 2023 (+1403.86 pp) and -1754.87% in the year ended Dec 31, 2022.
- The figure for the quarter ended Dec 31, 2025 represents the lowest quarterly EBITDA Margin since the quarter ended Dec 31, 2022.
- Business Quant data shows ACIU's EBITDA Margin at -1685.41% (quarter ended Sep 30, 2025), -1456.74% (quarter ended Jun 30, 2025) and -1920.10% (quarter ended Mar 31, 2025) in the three quarters before the quarter ended Dec 31, 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | AC Immune | 265.55 Mn | 265.55 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -4,161.24% |
| Sep 30, 2025 | -1,685.41% |
| Jun 30, 2025 | -1,456.74% |
| Mar 31, 2025 | -1,920.10% |
| Dec 31, 2024 | -1,605.89% |
| Sep 30, 2024 | 29.93% |
| Jun 30, 2024 | -2,996.07% |
| Dec 31, 2022 | -1,823,500.00% |
| Sep 30, 2022 | -331.09% |
| Dec 31, 2020 | -2,018.75% |
| Sep 30, 2020 | -1,639.54% |
| Jun 30, 2020 | -1,414.68% |
| Mar 31, 2020 | -56.46% |
| Dec 31, 2019 | -2,146.51% |
| Sep 30, 2019 | 54.78% |
| Jun 30, 2019 | -958.44% |
| Mar 31, 2019 | 80.55% |
| Dec 31, 2018 | 5,759.46% |
| Sep 30, 2018 | -517.09% |
| Jun 30, 2018 | -558.38% |
API Access
AC Immune EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ACIU&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "ACIU", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ACIU&period=max&api_key=YOUR_API_KEY");
const data = await res.json();